A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours

Trial Profile

A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs MP 0250 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 25 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Apr 2018.
    • 25 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2018.
    • 02 Dec 2016 Results of preliminary biomarker and pharmacokinetic analysis (n=24) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top